Bonothyrk

The source presents Bonothyrk as a peptide bioregulator associated with parathyroid tissue and proposed to influence skeletal and mineral physiology. The supplied material does not establish its molecular identity or demonstrate clinical benefit.

Parathyroid hormone contributes to the regulation of circulating calcium and phosphate through effects on bone and renal mineral handling. This established physiology provides context for the guide's claims but does not establish that Bonothyrk reproduces these effects.

The guide proposes activity resembling parathyroid hormone signaling, with possible effects on calcium balance and the processes of bone formation and resorption. It also attributes effects on renal mineral regulation, but supplies no experimental methods or results confirming these mechanisms for Bonothyrk.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 01 · Basic biology

A biological mechanism or molecular interaction is described. No claim about human outcomes.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide describes Bonothyrk as originating from parathyroid tissue and assigns it a role in mineral balance. It proposes potential relevance to osteoporosis, abnormal calcium levels, and skeletal repair. The guide also characterizes tolerability favorably while listing possible adverse effects, without supplying supporting study details.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 7, Introduction to Bioregulators (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The compound's composition, provenance, and relationship to parathyroid hormone remain unverified in the supplied material. Compound-specific mechanisms, clinical outcomes, and the applicability of evidence concerning other hormone-related products are unclear.

Safety data are limited, and the guide's favorable tolerability characterization is not substantiated by the supplied evidence. It lists nausea, lightheadedness, digestive symptoms, and disturbances in calcium balance, while raising a bone malignancy concern by analogy with some parathyroid hormone-related products rather than presenting Bonothyrk-specific findings. This information is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 7, Introduction to Bioregulators (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Parathyroid hormone and bone health”
• “Parathyroid hormone peptide osteoporosis”
• “PTH clinical applications in hypocalcemia”
• “Bonothyrk for bone healing and regeneration”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN